A Phase 2 interventional study of Dupilumab and placebo in Asthma, sponsored by Sanofi. Completed at 201 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 2, and was the 2nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2013.
This study's enrollment of 776 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 10th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2013, is one of 11 in phase 2, and was the 11th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
Secondary Objective:
To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to:
Total duration per participant of approximately 43 weeks including a screening period (14-21 days), a randomized treatment period (24 weeks), and a post-treatment period (16 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with a physician diagnosis of moderate to severe, uncontrolled asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and:
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: Dupilumab · Drug: ICS/LABA therapy · Drug: Salbutamol/albuterol · Drug: Levosalbutamol/levalbuterol
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: Dupilumab · Drug: ICS/LABA therapy · Drug: Salbutamol/albuterol · Drug: Levosalbutamol/levalbuterol
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: Dupilumab · Drug: placebo · Drug: ICS/LABA therapy · Drug: Salbutamol/albuterol · Drug: Levosalbutamol/levalbuterol
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: Dupilumab · Drug: placebo · Drug: ICS/LABA therapy · Drug: Salbutamol/albuterol · Drug: Levosalbutamol/levalbuterol
2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: placebo · Drug: ICS/LABA therapy · Drug: Salbutamol/albuterol · Drug: Levosalbutamol/levalbuterol
Solution for injection, Subcutaneous injection
Also known as: SAR231893, REGN668
Solution for injection, Subcutaneous injection
Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Drug page: Albuterol
Oral inhalation as needed
Drug page: Levalbuterol
Oral inhalation as needed
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Absolute Change From Baseline in FEV1 at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Percent Change From Baseline in FEV1 at Week 12: HEos-ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Percent Change From Baseline in FEV1 at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Annualized Event Rate of Severe Exacerbation During The Treatment Period: HEos-ITT Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 24
Annualized Event Rate of Severe Exacerbation During The Treatment Period: ITT Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 24
Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: HEos-ITT Population
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
Time frame: Baseline up to Week 24
Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: ITT Population
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
Time frame: Baseline up to Week 24
Annualized Event Rate of Loss of Asthma Control (LOAC) During The Treatment Period: HEos-ITT Population
LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in inhaled corticosteroid (ICS) \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 24
Annualized Event Rate of LOAC During The Treatment Period: ITT Population
LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 24
Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: HEos-ITT Population
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
Time frame: Baseline up to Week 24
Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: ITT Population
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
Time frame: Baseline up to Week 24
Change From Baseline in Morning Asthma Symptom Score at Week 12: HEos-ITT Population
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Time frame: Baseline, Week 12
Change From Baseline in Morning Asthma Symptom Score at Week 12: ITT Population
Morning asthma symptom score was determined using AM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Time frame: Baseline, Week 12
Change From Baseline in Evening Asthma Symptom Score at Week 12: HEos-ITT Population
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Time frame: Baseline, Week 12
Change From Baseline in Evening Asthma Symptom Score at Week 12: ITT Population
Evening asthma symptom score was determined using PM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Time frame: Baseline, Week 12
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 12: HEos-ITT Population
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: Baseline, Week 12
Change From Baseline in ACQ-5 Score at Week 12: ITT Population
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: Baseline, Week 12
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12: HEos-ITT Population
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time frame: Baseline, Week 12
Change From Baseline in AQLQ Global Score at Week 12: ITT Population
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time frame: Baseline, Week 12
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: HEos-ITT Population
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
Time frame: Baseline, Week 12
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: ITT Population
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
Time frame: Baseline, Week 12
The study was conducted at 201 sites in 16 countries. A total of 1532 participants were screened between June 2013 and June 2014, of which, 776 participants were randomized at 174 sites in 15 countries. 756 participants were screen failures mainly due to exclusion criteria met and inclusion criteria not met.
| Milestone | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Started | 158 | 157 | 150 | 157 | 154 |
| Treated | 158 | 156 | 148 | 157 | 150 |
| Completed 12-week study treatment | 153 | 149 | 141 | 146 | 143 |
| Completed | 146 | 149 | 137 | 142 | 135 |
| Not completed | 12 | 8 | 13 | 15 | 19 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 3 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 5 | 4 | 6 | 10 | 7 |
| Withdrew: Randomized but not treated | 0 | 1 | 2 | 0 | 4 |
| Withdrew: Other than specified above | 3 | 3 | 3 | 5 | 8 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.86 ± 0.68 | 1.77 ± 0.5 | 1.8 ± 0.52 | 1.87 ± 0.6 | 1.8 ± 0.49 |
| Week 12 | 2.13 ± 0.78 | 2.12 ± 0.54 | 2.26 ± 0.68 | 2.26 ± 0.70 | 2.09 ± 0.54 |
| Change from baseline at Week 12 | 0.18 ± 0.38 | 0.36 ± 0.46 | 0.45 ± 0.40 | 0.35 ± 0.43 | 0.26 ± 0.47 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.82 ± 0.55 | 1.85 ± 0.53 | 1.79 ± 0.52 | 1.86 ± 0.57 | 1.88 ± 0.54 |
| Week 12 | 2.01 ± 0.69 | 2.12 ± 0.59 | 2.12 ± 0.68 | 2.14 ± 0.69 | 2.07 ± 0.63 |
| Change from baseline at Week 12 | 0.13 ± 0.37 | 0.26 ± 0.39 | 0.32 ± 0.38 | 0.24 ± 0.4 | 0.20 ± 0.41 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Percent Change From Baseline in FEV1 at Week 12: HEos-ITT Population | 10.07 ± 19.65 | 25.29 ± 36.15 | 27.42 ± 25.68 | 20.68 ± 24.86 | 18.07 ± 29.18 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Percent Change From Baseline in FEV1 at Week 12: ITT Population | 7.04 ± 19.26 | 16.64 ± 27.78 | 19.15 ± 23.53 | 13.55 ± 23.01 | 13.04 ± 24.21 |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| exacerbation per participant-year | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Annualized Event Rate of Severe Exacerbation During The Treatment Period: HEos-ITT Population | 1.044 (0.572 to 1.904) | 0.201 (0.078 to 0.517) | 0.30 (0.133 to 0.678) | 0.678 (0.356 to 1.29) | 0.358 (0.158 to 0.809) |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| exacerbation per participant-year | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Annualized Event Rate of Severe Exacerbation During The Treatment Period: ITT Population | 0.897 (0.619 to 1.30) | 0.265 (0.157 to 0.445) | 0.269 (0.157 to 0.461) | 0.599 (0.369 to 0.907) | 0.415 (0.26 to 0.664) |
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
| probability of Severe Exacerbation | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Probability at Week 12 | 0.21 (0.122 to 0.314) | 0.082 (0.03 to 0.167) | 0.082 (0.03 to 0.167) | 0.094 (0.038 to 0.181) | 0.052 (0.014 to 0.13) |
| Probability at Week 24 | 0.287 (0.184 to 0.398) | 0.116 (0.051 to 0.21) | 0.082 (0.03 to 0.167) | 0.175 (0.093 to 0.278) | 0.125 (0.055 to 0.226) |
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
| probability of Severe Exacerbation | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Probability at Week 12 | 0.207 (0.147 to 0.274) | 0.092 (0.053 to 0.145) | 0.07 (0.036 to 0.119) | 0.112 (0.068 to 0.168) | 0.075 (0.04 to 0.125) |
| Probability at Week 24 | 0.266 (0.199 to 0.338) | 0.112 (0.068 to 0.169) | 0.091 (0.051 to 0.145) | 0.195 (0.136 to 0.262) | 0.16 (0.106 to 0.225) |
LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in inhaled corticosteroid (ICS) \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
| LOAC per participant-year | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Annualized Event Rate of Loss of Asthma Control (LOAC) During The Treatment Period: HEos-ITT Population | 1.312 (0.804 to 2.142) | 0.322 (0.153 to 0.677) | 0.446 (0.231 to 0.864) | 0.788 (0.458 to 1.355) | 0.424 (0.212 to 0.851) |
LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
| LOAC per participant-year | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Annualized Event Rate of LOAC During The Treatment Period: ITT Population | 1.107 (0.801 to 1.53) | 0.326 (0.206 to 0.515) | 0.347 (0.217 to 0.555) | 0.73 (0.508 to 1.048) | 0.563 (0.378 to 0.839) |
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
| probability of LOAC | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Probability at Week 12 | 0.30 (0.195 to 0.411) | 0.115 (0.05 to 0.208) | 0.113 (0.05 to 0.206) | 0.126 (0.059 to 0.22) | 0.052 (0.014 to 0.13) |
| Probability at Week 24 | 0.392 (0.275 to 0.507) | 0.166 (0.085 to 0.269) | 0.113 (0.05 to 0.206) | 0.207 (0.117 to 0.314) | 0.162 (0.079 to 0.269) |
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
| probability of LOAC | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Probability at Week 12 | 0.258 (0.192 to 0.329) | 0.112 (0.068 to 0.168) | 0.09 (0.051 to 0.144) | 0.145 (0.095 to 0.206) | 0.096 (0.055 to 0.15) |
| Probability at Week 24 | 0.338 (0.265 to 0.413) | 0.146 (0.095 to 0.207) | 0.112 (0.067 to 0.169) | 0.242 (0.177 to 0.314) | 0.209 (0.147 to 0.279) |
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.15 ± 0.82 | 1.45 ± 0.81 | 1.22 ± 0.81 | 1.31 ± 0.72 | 1.18 ± 0.82 |
| Week 12 | 0.83 ± 0.66 | 0.78 ± 0.88 | 0.70 ± 0.69 | 0.70 ± 0.78 | 0.63 ± 0.62 |
| Change from baseline at Week 12 | -0.29 ± 0.70 | -0.66 ± 0.67 | -0.55 ± 0.75 | -0.57 ± 0.63 | -0.57 ± 0.60 |
Morning asthma symptom score was determined using AM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.17 ± 0.79 | 1.25 ± 0.78 | 1.24 ± 0.81 | 1.33 ± 0.78 | 1.29 ± 0.82 |
| Week 12 | 0.90 ± 0.67 | 0.82 ± 0.79 | 0.79 ± 0.77 | 0.80 ± 0.73 | 0.72 ± 0.68 |
| Change from baseline at Week 12 | -0.23 ± 0.70 | -0.43 ± 0.70 | -0.46 ± 0.75 | -0.52 ± 0.65 | -0.54 ± 0.64 |
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.33 ± 0.83 | 1.72 ± 0.89 | 1.46 ± 0.73 | 1.52 ± 0.72 | 1.39 ± 0.87 |
| Week 12 | 0.95 ± 0.71 | 0.88 ± 0.91 | 0.89 ± 0.79 | 0.76 ± 0.84 | 0.69 ± 0.68 |
| Change from baseline at Week 12 | -0.35 ± 0.71 | -0.84 ± 0.87 | -0.62 ± 0.70 | -0.73 ± 0.77 | -0.69 ± 0.70 |
Evening asthma symptom score was determined using PM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.32 ± 0.81 | 1.47 ± 0.85 | 1.42 ± 0.79 | 1.50 ± 0.74 | 1.47 ± 0.84 |
| Week 12 | 1.02 ± 0.73 | 0.95 ± 0.88 | 0.95 ± 0.81 | 0.89 ± 0.79 | 0.89 ± 0.81 |
| Change from baseline at Week 12 | -0.27 ± 0.76 | -0.52 ± 0.79 | -0.52 ± 0.80 | -0.59 ± 0.79 | -0.54 ± 0.71 |
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 2.55 ± 0.84 | 2.98 ± 0.90 | 2.65 ± 0.74 | 2.69 ± 0.81 | 2.76 ± 0.91 |
| Week 12 | 1.52 ± 1.09 | 1.20 ± 0.96 | 1.20 ± 0.88 | 1.27 ± 0.91 | 1.39 ± 0.94 |
| Change from baseline at Week 12 | -1.03 ± 0.93 | -1.72 ± 1.14 | -1.40 ± 1.03 | -1.39 ± 1.02 | -1.38 ± 0.90 |
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 2.69 ± 0.80 | 2.80 ± 0.83 | 2.73 ± 0.82 | 2.70 ± 0.79 | 2.78 ± 0.84 |
| Week 12 | 1.55 ± 1.00 | 1.41 ± 1.02 | 1.38 ± 0.96 | 1.38 ± 0.86 | 1.49 ± 0.98 |
| Change from baseline at Week 12 | -1.11 ± 0.93 | -1.38 ± 1.10 | -1.35 ± 1.05 | -1.32 ± 1.02 | -1.24 ± 0.95 |
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 4.16 ± 1.27 | 3.82 ± 1.13 | 4.02 ± 1.15 | 3.99 ± 1.06 | 3.89 ± 1.88 |
| Week 12 | 5.05 ± 1.22 | 5.35 ± 1.21 | 5.41 ± 1.06 | 5.06 ± 1.19 | 5.05 ± 1.29 |
| Change from baseline at Week 12 | 0.80 ± 1.02 | 1.54 ± 1.18 | 1.42 ± 0.97 | 1.08 ± 0.97 | 1.16 ± 1.01 |
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
| scores on a scale | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 4.12 ± 1.10 | 3.91 ± 1.13 | 4.03 ± 1.15 | 4.02 ± 1.01 | 4.00 ± 1.09 |
| Week 12 | 5.00 ± 1.10 | 5.13 ± 1.22 | 5.22 ± 1.11 | 5.04 ± 1.13 | 5.03 ± 1.12 |
| Change from baseline at Week 12 | 0.86 ± 0.99 | 1.25 ± 1.10 | 1.19 ± 1.05 | 1.03 ± 1.02 | 0.98 ± 1.02 |
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
| inhalations per day | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 2.53 ± 2.77 | 3.61 ± 3.56 | 3.02 ± 2.85 | 3.15 ± 2.70 | 2.42 ± 2.75 |
| Week 12 | 1.88 ± 2.53 | 2.14 ± 3.22 | 2.15 ± 2.67 | 1.85 ± 2.75 | 1.36 ± 1.76 |
| Change from baseline at Week 12 | -0.51 ± 1.74 | -1.47 ± 2.31 | -0.93 ± 2.31 | -1.49 ± 2.37 | -1.01 ± 2.00 |
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
| inhalations per day | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 2.72 ± 2.73 | 3.25 ± 3.15 | 2.98 ± 2.74 | 3.36 ± 3.43 | 3.01 ± 2.87 |
| Week 12 | 2.20 ± 2.57 | 2.30 ± 3.02 | 2.03 ± 2.46 | 2.09 ± 2.73 | 1.99 ± 2.42 |
| Change from baseline at Week 12 | -0.44 ± 1.75 | -0.95 ± 2.05 | -0.99 ± 2.27 | -1.35 ± 2.84 | -0.92 ± 2.16 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Baseline | 1.79 ± 0.42 | 1.9 ± 0.55 | 1.79 ± 0.53 | 1.85 ± 0.56 | 1.94 ± 0.56 |
| Week 12 | 1.92 ± 0.61 | 2.12 ± 0.63 | 2.02 ± 0.67 | 2.05 ± 0.68 | 2.06 ± 0.68 |
| Change from baseline at Week 12 | 0.09 ± 0.36 | 0.19 ± 0.31 | 0.23 ± 0.33 | 0.16 ± 0.36 | 0.17 ± 0.36 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 40) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/158 (0%) | 9/158 (5.7%) | 88/158 (55.7%) |
| Dupilumab 300 mg q2w | 0/156 (0%) | 13/156 (8.3%) | 95/156 (60.9%) |
| Dupilumab 200 mg q2w | 0/148 (0%) | 10/148 (6.8%) | 81/148 (54.7%) |
| Dupilumab 300 mg q4w | 2/157 (1.3%) | 16/157 (10.2%) | 96/157 (61.1%) |
| Dupilumab 200 mg q4w | 0/150 (0%) | 6/150 (4%) | 74/150 (49.3%) |
| Event | Placebo | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 4/158 | 1/156 | 5/148 | 2/157 | 2/150 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/158 | 0/156 | 2/148 | 1/157 | 0/150 |
| GastroenteritisInfections and infestations | 0/158 | 2/156 | 0/148 | 0/157 | 0/150 |
| EpiglottitisInfections and infestations | 0/158 | 0/156 | 1/148 | 0/157 | 0/150 |
| SinusitisInfections and infestations | 0/158 | 0/156 | 1/148 | 0/157 | 0/150 |
| HypertensionVascular disorders | 0/158 | 0/156 | 1/148 | 0/157 | 0/150 |
| ColitisGastrointestinal disorders | 0/158 | 0/156 | 1/148 | 0/157 | 0/150 |
| Procedural painInjury, poisoning and procedural complications | 0/158 | 0/156 | 1/148 | 0/157 | 0/150 |
| Benign neoplasm of thyroid glandNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/158 | 0/156 | 0/148 | 0/157 | 1/150 |
| Atrioventricular block completeCardiac disorders | 0/158 | 0/156 | 0/148 | 0/157 | 1/150 |
| Event | Placebo | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w |
|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 12/158 | 34/156 | 21/148 | 12/157 | 13/150 |
| Upper respiratory tract infectionInfections and infestations | 28/158 | 20/156 | 22/148 | 19/157 | 22/150 |
| HeadacheNervous system disorders | 20/158 | 17/156 | 17/148 | 19/157 | 9/150 |
| BronchitisInfections and infestations | 16/158 | 19/156 | 11/148 | 11/157 | 10/150 |
| NasopharyngitisInfections and infestations | 15/158 | 16/156 | 15/148 | 19/157 | 9/150 |
| Injection site painGeneral disorders | 7/158 | 14/156 | 7/148 | 6/157 | 5/150 |
| InfluenzaInfections and infestations | 5/158 | 9/156 | 6/148 | 13/157 | 10/150 |
| SinusitisInfections and infestations | 11/158 | 6/156 | 5/148 | 13/157 | 12/150 |
| Back painMusculoskeletal and connective tissue disorders | 6/158 | 12/156 | 8/148 | 4/157 | 7/150 |
| Injection site pruritusGeneral disorders | 5/158 | 12/156 | 10/148 | 0/157 | 3/150 |
| Age, Continuous(years) | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w | Total |
|---|---|---|---|---|---|---|
| Mean | 49 ± 12.7 | 47.5 ± 12.4 | 51 ± 13.4 | 47.9 ± 13.1 | 47.9 ± 13.1 | 48.6 ± 13.0 |
| Sex: Female, Male(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w | Total |
|---|---|---|---|---|---|---|
| Female | 104 | 103 | 96 | 100 | 87 | 490 |
| Male | 54 | 54 | 54 | 57 | 67 | 286 |
| Race (NIH/OMB)(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 25 | 22 | 25 | 23 | 20 | 115 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 9 | 5 | 9 | 12 | 7 | 42 |
| White | 119 | 129 | 114 | 120 | 125 | 607 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 1 | 1 | 1 | 2 | 10 |
| Race/Ethnicity, Customized(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w | Total |
|---|---|---|---|---|---|---|
| Hispanic Or Latino | 31 | 29 | 29 | 33 | 26 | 148 |
| Not Hispanic Or Latino | 127 | 128 | 121 | 124 | 128 | 628 |
| Number of Participants According to Blood Eosinophil Count(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 200 mg q4w | Total |
|---|---|---|---|---|---|---|
| <0.3 G/L | 90 | 93 | 85 | 91 | 92 | 451 |
| >=0.3 G/L | 68 | 64 | 65 | 66 | 62 | 325 |
Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2013, a primary completion of Nov 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 2 years 7 months after primary completion. A results delay was requested in Nov 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab